Hutchmed (China) (HKG:0013) recorded a rise in attributable profit for the year 2025 to $456.9 million from $37.7 million a year prior, according to a Thursday Hong Kong bourse filing.
Earnings per share stood at $0.52 in the period, up from $0.04 in the last corresponding year.
The biotech firm's revenue slipped 13% to $548.5 million from $630.2 million previously.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.